Truist Securities Maintains Buy on Intellia Therapeutics, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) with a $120 price target.
June 24, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Joon Lee maintains a Buy rating on Intellia Therapeutics with a $120 price target.
The reaffirmation of a Buy rating and a $120 price target by Truist Securities is a positive signal for investors, likely boosting short-term confidence and demand for NTLA shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100